Mobile

A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced...

Update Il y a 4 ans
Reference: ISRCTN82487767

A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Not provided at time of registration

Inclusion criteria

  • Topic: Neurological; Subtopic: Neurological (all Subtopics); Disease: Nervous system disorders

Links